DK1779858T3 - Anvendelse af selenforbindelser, især selengær, til forandring af kognitiv funktion - Google Patents

Anvendelse af selenforbindelser, især selengær, til forandring af kognitiv funktion

Info

Publication number
DK1779858T3
DK1779858T3 DK06007443.2T DK06007443T DK1779858T3 DK 1779858 T3 DK1779858 T3 DK 1779858T3 DK 06007443 T DK06007443 T DK 06007443T DK 1779858 T3 DK1779858 T3 DK 1779858T3
Authority
DK
Denmark
Prior art keywords
selenium
cognitive function
present
yeast
compounds
Prior art date
Application number
DK06007443.2T
Other languages
English (en)
Inventor
Lyons Thomas Pearse
Ronan Power
Original Assignee
Alltech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alltech Inc filed Critical Alltech Inc
Application granted granted Critical
Publication of DK1779858T3 publication Critical patent/DK1779858T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
DK06007443.2T 2005-10-14 2005-11-07 Anvendelse af selenforbindelser, især selengær, til forandring af kognitiv funktion DK1779858T3 (da)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US72701805P 2005-10-14 2005-10-14
US72692205P 2005-10-14 2005-10-14
US72695105P 2005-10-14 2005-10-14
US72701505P 2005-10-14 2005-10-14
EP05024235A EP1774972B1 (en) 2005-10-14 2005-11-07 Use of selenium yeasts in the treatment of Alzheimers disease

Publications (1)

Publication Number Publication Date
DK1779858T3 true DK1779858T3 (da) 2013-02-04

Family

ID=35734026

Family Applications (2)

Application Number Title Priority Date Filing Date
DK05024235.3T DK1774972T3 (da) 2005-10-14 2005-11-07 Anvendelse af selengær ved behandlingen af Alzheimers sygdom
DK06007443.2T DK1779858T3 (da) 2005-10-14 2005-11-07 Anvendelse af selenforbindelser, især selengær, til forandring af kognitiv funktion

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK05024235.3T DK1774972T3 (da) 2005-10-14 2005-11-07 Anvendelse af selengær ved behandlingen af Alzheimers sygdom

Country Status (14)

Country Link
EP (5) EP1779856A1 (da)
JP (1) JP4753683B2 (da)
CN (2) CN102764279B (da)
AT (1) ATE547107T1 (da)
AU (1) AU2005227420B2 (da)
CY (1) CY1112790T1 (da)
DK (2) DK1774972T3 (da)
ES (2) ES2382334T3 (da)
HR (1) HRP20120337T1 (da)
PL (2) PL1779858T3 (da)
PT (2) PT1779858E (da)
RS (2) RS52257B (da)
SI (1) SI1774972T1 (da)
TW (1) TWI319708B (da)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007231547B2 (en) 2006-03-29 2012-07-12 Velacor Therapeutics Pty Ltd Treatment of neurodegenerative diseases
EP2012806A4 (en) * 2006-04-24 2010-07-28 Alltech Inc METHODS AND COMPOSITIONS FOR MODIFYING CELLULAR FUNCTION
PL2698166T3 (pl) 2006-10-10 2016-03-31 Regenesance B V Hamowanie układu dopełniacza służące do lepszej regeneracji nerwów
US7696251B2 (en) 2007-02-12 2010-04-13 Incorporated National University Iwate University Method for inhibiting neuronal cell death induced by oxidative glutamate toxicity
WO2008119109A1 (en) * 2007-03-29 2008-10-09 Velacor Therapeutics Pty Ltd Treatment of neurological disorders
US8987245B2 (en) 2008-04-02 2015-03-24 Jonathan R. Brestoff Parker Composition and method for affecting obesity and related conditions
US8598150B1 (en) 2008-04-02 2013-12-03 Jonathan R. Brestoff Composition and method for affecting obesity and related conditions
US9493834B2 (en) 2009-07-29 2016-11-15 Pharnext Method for detecting a panel of biomarkers
US9320768B2 (en) * 2009-08-26 2016-04-26 Milmed Ab Composition for treatment of neurodegenerative diseases or disorders, method and use comprising electromagnetically irradiated yeast
US8263752B2 (en) * 2010-03-18 2012-09-11 Alltech, Inc. Methods for separating soluble selenoglycoproteins
WO2012095548A2 (es) * 2011-01-13 2012-07-19 Centro De Investigación Biomédica En Red De Enfermedades Neurodegenerativas (Ciberned) Compuestos para el tratamiento de enfermedades neurodegenerativas
SG10202101918RA (en) * 2013-03-15 2021-03-30 Alltech Inc Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction
EP3019240B1 (en) 2013-07-09 2024-03-13 Annexon, Inc. Anti-complement factor c1q antibodies and uses thereof
CN103848898B (zh) * 2014-02-17 2016-01-27 南昌大学 双酚A的抗原模拟表位Ph3及其应用
BR112016020233B1 (pt) * 2014-03-14 2022-07-19 Alltech Inc. Composições de compostos seleno orgânicos e seus usos
KR102626877B1 (ko) 2014-11-05 2024-01-19 애넥슨, 인코포레이티드 인간화 항-보체 인자 c1q 항체 및 이의 용도
CN104825498A (zh) * 2015-03-30 2015-08-12 安徽省华信生物药业股份有限公司 硒酵母在阿尔茨海默病防治中的应用
WO2017048252A1 (en) * 2015-09-15 2017-03-23 Alltech, Inc. Compositions of selenoorganic compounds and methods of use thereof
AU2016361517B2 (en) 2015-11-24 2023-12-14 Annexon, Inc. Anti-complement factor C1q Fab fragments and uses thereof
WO2017096049A1 (en) 2015-12-03 2017-06-08 The University Of North Carolina At Pembroke Materials for cathepsin b enhancement and methods of use
CA3075035A1 (en) * 2017-09-07 2019-03-14 The Children's Hospital Of Philadelphia Compositions and methods for treatment of hereditary cystatin c amyloid angiopathy (hccaa) and other neurodegenerative disorders associated with aberrant amyloid deposits
CN111458517B (zh) * 2020-03-13 2022-08-16 深圳大学 Selenof作为阿尔茨海默病药物靶点的应用
PL440896A1 (pl) 2022-04-11 2023-10-16 Uniwersytet Gdański Genisteina do zastosowania w zapobieganiu utraty pamięci i zdolności poznawczych ludzi zdrowych w wyniku stopniowych występujących fizjologicznie u osób zdrowych procesów starzenia się mózgu z wiekiem jako czynnik zapobiegający i zmniejszający odkładanie się szkodliwych nierozpuszczalnych agregatów i złogów białek w mózgu, zwłaszcza beta-amyloidu

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT397200B (de) * 1988-06-03 1994-02-25 Birkmayer Joerg Ddr Verwendung von selenmethionin zur herstellung eines arzneimittels
GB9001121D0 (en) * 1990-01-18 1990-03-21 Efamol Holdings Efa compositions and therapy
US5221545A (en) 1992-03-09 1993-06-22 Abbott Laboratories Method of providing selenium in a nutritional product
DE4413839C1 (de) * 1994-04-21 1995-10-19 Fritz Koch Pharma Gmbh Dr Med Kombinationspräparat
JPH09323939A (ja) * 1996-06-03 1997-12-16 R T Ee Assoc Kk 抗痴呆剤
AU720643B2 (en) * 1996-08-13 2000-06-08 P.N. Gerolymatos S.A. Use of the chelating agent clioquinol for the manufacture of a pharmaceutical composition for the treatment of Alzheimer's disease
US6197295B1 (en) 1996-09-25 2001-03-06 Viva America Marketing Corporation Dietary supplementation with, and methods for administration of yeast-derived selenium product
JP2002513383A (ja) * 1997-05-21 2002-05-08 スローン−ケタリング・インスティテュート・フォー・キャンサー・リサーチ 患者の脳組織でのアスコルビン酸の濃度を増加させる方法
JPH11199599A (ja) * 1997-12-09 1999-07-27 Adriel Dell Calpio Carlos 補体活性阻害性ペプチドおよび抗補体剤
FR2774596B1 (fr) * 1998-02-11 2000-03-17 Rhone Poulenc Rorer Sa Utilisation de composes selenies dans la prevention et le traitement de la maladie d'alzheimer
AU6384099A (en) * 1998-08-31 2000-03-21 Proteotech, Inc. Blended compositions for treatment of alzheimer's disease and other amyloidoses
JP2003530066A (ja) * 1999-04-06 2003-10-14 ザ・レジェンツ・オブ・ザ・ユニバーシティー・オブ・カリフォルニア ヒトニューロゲニン３をコードするヌクレオチド配列
CA2325041A1 (en) * 2000-11-17 2002-05-17 Eddie Lo Ultra-vit. plus
DE10158180A1 (de) * 2001-11-28 2003-09-11 Biovision Ag Verfahren zum Nachweis von Morbus Alzheimer und zur Unterscheidung von Morbus Alzheimer gegenüber anderen demenziellen Erkrankungen, zugehörige Peptide und deren Verwendung
KR101089591B1 (ko) * 2001-12-07 2011-12-05 제론 코포레이션 인간 배아 줄기세포 유래의 섬세포
GB0202900D0 (en) * 2002-02-07 2002-03-27 Laxdale Ltd Novel formulations of drugs
DK174835B1 (da) * 2002-03-15 2003-12-15 Pharma Nord Aps Selengærprodukt, fremgangsmåde til fremstilling af et selengærprodukt samt anvendelse af produktet til fremstilling af en fødevare, et kosttilskud, eller et lægemiddel
CN1403017A (zh) * 2002-10-24 2003-03-19 田轩 富硒魔芋绿茶保健食品
US6911550B2 (en) 2003-02-21 2005-06-28 Zinpro Corporation Derivatives of seleno-amino acids with improved bioavailability and method for their preparation
CN1440665A (zh) * 2003-04-01 2003-09-10 宁夏长宁实业（集团）有限公司乳业分公司 富含硒及超氧化物歧化酶乳制品及其生产方法
JP2004344079A (ja) * 2003-05-23 2004-12-09 Sceti Co Ltd チャーガを含有する健康補助食品
JP2007528857A (ja) * 2003-07-11 2007-10-18 ミリアド ジェネティクス， インコーポレイテッド アルツハイマー病の処置のための薬学的方法、投与レジメンおよび投薬形態
US20050069594A1 (en) 2003-08-11 2005-03-31 Jan Lubinski Pharmaceutical compositions and methods for the prevention of breast and ovarian cancer
UY28650A1 (es) * 2003-12-05 2005-02-28 Forest Laboratories Memantina para la prevencion o disminucion de la conducta suicida y para el tratamiento de la depresion mayor asociada con esta conducta
CN1569123A (zh) * 2004-04-30 2005-01-26 成进学 用蛇、蜂、宏、微量元素强化中药方剂的内服功能性药剂及其生产工艺

Also Published As

Publication number Publication date
SI1774972T1 (sl) 2012-06-29
RS52257B (en) 2012-10-31
PL1779858T3 (pl) 2013-06-28
JP4753683B2 (ja) 2011-08-24
AU2005227420A1 (en) 2007-05-03
EP1774972B1 (en) 2012-02-29
EP1779858A1 (en) 2007-05-02
CN102764279A (zh) 2012-11-07
ATE547107T1 (de) 2012-03-15
EP1774972A1 (en) 2007-04-18
ES2402365T3 (es) 2013-05-03
ES2382334T3 (es) 2012-06-07
CN102764279B (zh) 2015-04-01
CY1112790T1 (el) 2016-02-10
EP2087895A1 (en) 2009-08-12
CN101073584A (zh) 2007-11-21
EP1779858B1 (en) 2013-01-09
EP1779857A1 (en) 2007-05-02
RS52666B (en) 2013-06-28
PT1779858E (pt) 2013-04-08
EP1779856A1 (en) 2007-05-02
HRP20120337T1 (hr) 2012-05-31
AU2005227420B2 (en) 2013-05-09
DK1774972T3 (da) 2012-05-14
JP2007106732A (ja) 2007-04-26
PT1774972E (pt) 2012-05-21
TWI319708B (en) 2010-01-21
PL1774972T3 (pl) 2012-08-31
TW200714277A (en) 2007-04-16
CN101073584B (zh) 2012-10-10

Similar Documents

Publication Publication Date Title
DK1779858T3 (da) Anvendelse af selenforbindelser, især selengær, til forandring af kognitiv funktion
DOP2009000134A (es) Compuestos bicíclicos y su uso como anti-diabéticos
MX2008008152A (es) Compuestos heterociclicos biciclicos.
NO20055130L (no) Aminocykloheksyleter-forbindelser og deres anvendelse
WO2006124748A3 (en) Multicyclic compounds and methods of their use
CY1113212T1 (el) Σπειροκυκλικες ενωσεις ως αναστολεις αφυδρογονασης τυπου 1 11-βητα υδροξυλ στεροειδους
EA200970581A1 (ru) Кристаллическое твёрдое основание разагилина
TW200608961A (en) Methods and reagents for the treatment of metabolic disorders
HN2008000311A (es) Formas cristalinas de 4-metil-n-[3-(4-metil-imidazol-1-il)-5-trifluorometil-fenil]-3-(4-piridin-3-il-pirimidin-2-ilamino)-benzamida
MY142988A (en) Novel aminobenzophenone compounds
GEP20084520B (en) Use of retinyl derivatives and compositions thereof for treating ophthalmic diseases
WO2007127273A3 (en) Methods and compositions for altering cell function
WO2007146965A3 (en) Compounds for the treatment of periodontal disease
GB0515353D0 (en) Food
EP1814535A4 (en) NITROSED AND NITROSYLATED COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING EYE DISEASES
WO2008149353A3 (en) Telomerase activating compounds and methods of use thereof
TW200716088A (en) Formulations and methods for treating amyloidosis
DE602006006950D1 (de) Zusammensetzungen, Verwendungen und Kit für die Behandlung von Dermatitis
WO2005117543A3 (en) N-sulfonylcarboximidamide apoptosis promoters
DE602006008788D1 (de) Verbindungen
GT200600173A (es) Forma purificada de tranaproget
NO20074528L (no) Substituerte pyrroler, sammensetninger, fremgangsmate for fremstilling og anvendelse av samme
WO2006078833A3 (en) Novel coumarin derivatives as ion channel openers
WO2007056570A3 (en) Levodopa compositions
ATE425212T1 (de) Tocopherolzusammensetzungen und verwendung